Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
Preet Paul Singh , Qian Shi , Nathan R. Foster , Axel Grothey
Oncologist 21 ( 12) 1509 -1521
19
2016
Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases.
Erica S. Tsang , Jonathan M. Loree , Janine M. Davies , Sharlene Gill
Canadian Journal of Gastroenterology & Hepatology 2020 5104082
2
2020
Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)
Jérôme Galon , R. Alberts Steven , A. Sinicrope Frank , Qian Shi
Annals of Oncology 28
1
2017
Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?
Sharlene Gill , Frank A. Sinicrope
Seminars in Oncology 32 ( 1) 24 -34
44
2005
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators
Aditya Bardia , Charles Loprinzi , Axel Grothey , Garth Nelson
Seminars in Oncology 37 ( 1) 39 -46
19
2010
Outcomes in Elderly Patients with Advanced Colorectal Cancer Treated with Capecitabine: A Population-Based Analysis
Cheryl Ho , Kathy Ng , Susan O'Reilly , Sharlene Gill
Clinical Colorectal Cancer 5 ( 4) 279 -282
37
2005
Capecitabine-Induced Cerebellar Toxicity
Daniel Renouf , Sharlene Gill
Clinical Colorectal Cancer 6 ( 1) 70 -71
25
2006
Trends in Chemotherapy Utilization for Colorectal Cancer
Daniel Renouf , Hagen Kennecke , Sharlene Gill
Clinical Colorectal Cancer 7 ( 6) 386 -389
24
2008
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Sharlene Gill , Charles L. Loprinzi , Daniel J. Sargent , Stephan D. Thomé
Journal of Clinical Oncology 22 ( 10) 1797 -1806
1,263
2004
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker , Louise Nott , Takayuki Yoshino , Sharlene Gill
The Lancet Gastroenterology & Hepatology 3 ( 4) 263 -270
55
2018
The identification of Lynch syndrome in British Columbia.
Carol M Cremin , Linlea Armstrong , Sharlene Gill , David Huntsman
Canadian Journal of Gastroenterology & Hepatology 23 ( 11) 761 -767
3
2009
Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study.
Aaron Sha , Shirin Abadi , Sharlene Gill
Journal of Oncology Pharmacy Practice 24 ( 7) 501 -506
6
2018
Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
Kenneth S. Wilson , Catherine A. Fitzgerald , Jeff B. Barnett , B. Pharm
Cancer Investigation 25 ( 8) 711 -714
11
2007
Navigating later lines of treatment for advanced colorectal cancer - optimizing targeted biological therapies to improve outcomes.
Sharlene Gill , Scot Dowden , Bruce Colwell , Loretta L. Collins
Cancer Treatment Reviews 40 ( 10) 1171 -1181
16
2014
Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation
Sharlene Gill , Noralane M. Lindor , Lawrence J. Burgart , Regenia Smalley
Clinical Cancer Research 11 ( 18) 6466 -6471
50
2005
Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review
Khalid Saad El Din , Jonathan M. Loree , Eric C. Sayre , Sharlene Gill
BMC Cancer 20 ( 1) 1 -14
77
2020
Utilization of capecitabine-oxaliplatin (CAPOX) versus infusional 5-fluorouracil and oxaliplatin (FFOX) in the adjuvant treatment (AT) of resected high-risk colon cancer.
Aaron Sha , Shirin Abadi , Sharlene Gill
Journal of Clinical Oncology 33
2015
Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort.
Theresa W. Chan , Carl Brown , Cheryl C. Ho , Sharlene Gill
American Journal of Clinical Oncology 33 ( 1) 52 -55
23
2010
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX
Renata D. Peixoto , Maria Ho , Daniel J. Renouf , Howard J. Lim
American Journal of Clinical Oncology 40 ( 5) 507 -511
43
2017
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Maria Yi Ho , Hagen F. Kennecke , Daniel J. Renouf , Winson Y. Cheung
American Journal of Clinical Oncology 40 ( 6) 552 -554
17
2017